BioViva

BioViva is an American biotechnology gene therapy company, based in Bainbridge Island, Washington, researching treatments to stop or reverse the aging process in humans.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

BioViva is an American biotechnology gene therapy company, based in Bainbridge Island, Washington, researching treatments to stop or reverse the aging process in humans. Parrish's decision to be 'patient zero' and test the company's technology on herself in a personalized N=1 study was a response to her son's diagnosis of Type 1 Diabetes.

Early life

After finding no curative course Parrish looked into genetics. She claims that every gene BioViva targets will also treat a childhood disease. Dr. Lawrence Altman, author of Who Goes First?

The Story of Self-Experimentation in Medicine has said, "N's of 1 have had their value through history, and will. But you're not going to license a drug based on an N-of-1." Her treatment, labelled as self-experimentation, was highly controversial.

Though controversial, Dr Barry Marshall went on to win a Nobel prize for such an effort in the treatment of stomach ulcers. As the requirements to progress to human trials had not started, the US Food and Drug Administration did not authorize Parrish's experiments. Parrish traveled to Colombia for the treatments.

In 2016 some initially criticized BioViva's release of data claiming an extension of Parrish's leukocyte telomeres following her therapy, stating that the aforementioned extension is within the error change for telomere measurements. Dr. Bradley Johnson, Associate Professor of Pathology and Lab Medicine at the University of Pennsylvania said, "Telomere length measurements typically have low precision, with variation in measurements of around 10 percent, which is in the range of the reported telomere lengthening apparently experienced by Elizabeth Parrish."

In 2022 BioViva released a peer reviewed paper that showed lengthening of telomeres over years and the press has changed mass scientific opinion in the company's favor . The Hallmarks of Aging papers seems to have created a platform in which to launch BioViva's gene therapies as their targets are these hallmarks.

Telomeres were once thought oncogenic or cancer causing, but both María Blasco and BioViva added to evidence that it does not increase cancer risk in model organisms. The telomeres' function is to maintain chromosomal integrity and provide a substrate for DNA replication (thereby allowing for cellular multiplication), however, telomere shortening causes shortening of cellular lifetime which helps to avoid cancerous mutations in cells.

Duncan Baird, a professor of Cancer and Genetics at Cardiff University's School of Medicine, states, "Meddling with a fundamentally important tumor-suppressive mechanism that has evolved in long-lived species like ours doesn't strike me as a particularly good idea." George M. Martin, Professor of Pathology at the University of Washington, had agreed to be an adviser to the company, but resigned upon hearing about Parrish's self-experiments.

But other advisors for BioViva have stayed, including Prof George Church of Harvard who has continued to advocate for the company and has shown BioViva's most recent data in several virtual talks as of 2024. In 2015, Antonio Regalado, a reporter for the MIT Technology Review states, "The experiment seems likely to be remembered as either a new low in medical quackery or, perhaps, the unlikely start of an era in which naive people receive genetic modifications not just to treat disease, but to reverse aging."

Regalado seems to have changed his mind and reversed his criticism; he has since written several articles in support of the science. Since then several of the biggest companies and a few billionaires have started on the same pursuit including Jeff Bezos multi billion dollar endeavor called Altos and Google's anti-aging company called Calico.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1370302596 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

19 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.